Romainville, France, April the 2nd, 2007
Press Release
Cellectis S.A. Announces its 2007 Financial and Investor Relations Calendar.
Romainville, France - April the 2nd, 2007 - Cellectis S.A., a biotechnology company specializing in genome engineering and developing a new range of products for the custom rewriting of DNA sequences for the research, healthcare and industrial sectors, today announces its tentative financial and investor relations calendar for 2007.
The tentative financial calendar was set as follows:
| April 17, 2007 | Publication of 2006 Annual Results |
|---|
| May 30, 2007 | Shareholders Annual Meeting |
|---|
| September 25, 2007 | Publication of mid-year financial statements as of June 30, 2007
Publication of the first letter to shareholders |
|---|
| November 13, 2007 | Publication of revenue for 3Q200 |
|---|
| January, 2008 | Publication of the first letter to shareholder |
|---|
| February, 2008 | Publication of revenue for 4Q2007 and for fiscal year 2007 |
|---|
| March, 2008 | Publication of 2007 Annual Result |
|---|
An Investor's section is already available on the Company's site (www.cellectis.com). It will be completed within the next few weeks, and regularly updated, with all publicly available corporate information on Cellectis.
Practical information:
| ISIN Code | FR0010425595 |
|---|
| Ticker code | ALCLS |
|---|
About Cellectis S.A.
Cellectis S.A. is a biotech company developing innovative, proprietary technologies for genome engineering: a new class of "molecular scissors" - Meganuclease™ enzymes - capable of recognizing, binding and cutting DNA with extremely high specificity. The company is developing and commercializing Meganuclease Recombination Systems (MRSs) which combine these molecular scissors with a DNA matrix for targeting and modifying a gene of interest in vivo (and without affecting the rest of the genome) via the action of the cell's natural maintenance and repair system. By developing this first-in-class technology on the industrial scale, Cellectis has opened the way to rational genome engineering, which seeks to accurately and reliability insert, modify, modulate or correct genes in any living organism - without the addition of foreign genes, which are often imprecise and poorly tolerated. Cellectis now holds a portfolio of 8 MRSs in development, of which 5 have a therapeutic focus.
Cellectis is a spin-off from the Pasteur Institute in Paris, which has granted the company exclusive rights to 26 of the 27 granted patents and 38 of the 69 pending applications in its current portfolio, including one which will fall into the public domain in 2009, followed by 6 others in 2010. Before its IPO, Cellectis had already raised 17.5 million euros in two rounds (in 2000 and 2002/2005) to support its R&D and commercial development. The company's principal shareholders are AGF Private Equity, BankInvest Biomedical Venture, Edmond de Rothschild Investment Partners, Kaminvest Holding and Odyssée Venture. To date, Cellectis has signed 45 collaboration agreements and alliances worldwide with pharma companies (including AstraZeneca, Merck & Co., Wyeth and Shire), agrochemical groups (including Bayer, DuPont and BASF) and biotech companies (including Genentech, Regeneron and Lexicon Genetics). Cellectis' corporate headquarters are located on the Biocitech biopark at Romainville near Paris. It currently has 40 staff, including 16 PhDs.
For more information on Cellectis, visit our web site: www.cellectis.com
Copyright © Cellectis 2007. All rights reserved.
|
